Trial Profile
A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Third Party Open, Multiple Dose Escalation, Single Center Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Subcutaneously Administered ELX-02 in Independent Consecutive Cohorts of Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Feb 2022
Price :
$35
*
At a glance
- Drugs Exaluren (Primary)
- Indications Cystic fibrosis; Cystinosis
- Focus Adverse reactions
- Sponsors Eloxx Pharmaceuticals
- 26 Jan 2021 According to an Eloxx Pharmaceuticals media release, scientific manuscript on the results from this study was published in the Journal of Clinical Pharmacology in Drug Development.
- 31 Oct 2019 Results presented in the Eloxx Pharmaceuticals Media Release.
- 31 Oct 2019 According to a Eloxx Pharmaceuticals media release, data from this trial were presented at the Eloxx Pharmaceuticals media release.